PD-1– and CTLA-4–Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

PD-1– and CTLA-4–Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses

Published:2013-12-11 Issue:215 Volume:5 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Fedorov Victor D.¹²,Themeli Maria¹,Sadelain Michel¹³

Affiliation:

1. Center for Cell Engineering, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, NY 10065, USA.

2. Tri-Institutional MSTP Program (MSKCC, Rockefeller University, Weill-Cornell Medical College), New York, NY 10065, USA.

3. Molecular Pharmacology and Chemistry Program, MSKCC, New York, NY 10065, USA.

Abstract

Human T cells that are reversibly inhibited upon contact with antigen protect bystander tissues from immune destruction.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference56 articles.

1. Cancer Immunotherapy: A Treatment for the Masses

2. Adoptive immunotherapy for cancer: harnessing the T cell response

3. The promise and potential pitfalls of chimeric antigen receptors

4. Engineered T cells for anti-cancer therapy

5. Advances in graft-versus-host disease biology and therapy

Cited by 599 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting;Molecular Therapy;2024-09

2. Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignancies;Blood Reviews;2024-09

3. Current Insights into CAR T-Cell-Based Therapies for Myelodysplastic Syndrome;Pharmaceutical Research;2024-08-26

4. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors;Cellular & Molecular Immunology;2024-08-12

5. Beyond CAR-T: The rise of CAR-NK cell therapy in asthma immunotherapy;Journal of Translational Medicine;2024-08-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3